KU32 | 956498-70-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: KU32
• 英文别名: N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)acetamide；N-[7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-8-methyl-2-oxochromen-3-yl]acetamide
• CAS: 956498-70-7
• 化学式: C₂₀H₂₅NO₈
• 分子量: 407.42
• InChiKey: KJAWXHNSLFJNTM-BUIAKZPTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  124
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  、 乙酸酐 在 甲醇 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以0.03 g的产率得到KU32
  参考文献：
  名称：

  Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain

  摘要：

  Novologues KU-32和KU-596结合在Hsp90的C末端结构域，并利用长程的变构网络来调节伴侣作用周期。

  DOI：

  10.1039/c8md00151k

文献信息

• Heat shock protein 90 inhibitor dosing methods
  申请人：Rajewski Roger A.

  公开号：US20100022635A1

  公开（公告）日：2010-01-28

  The disclosure provides novel dosing regimens for Hsp90 inhibitors for use in the treatment or prevention of a neurodegenerative disorder, an autoimmune disorder, or cancer. The methods involve administering one or more doses of a therapeutically effective amount of at least one Hsp90 inhibitor to a subject in need thereof such that no more than a single dose is administered within a period of about 7 days.

  该披露提供了新型的Hsp90抑制剂用于治疗或预防神经退行性疾病、自身免疫疾病或癌症的剂量方案。该方法涉及向需要治疗的受试者施用至少一种Hsp90抑制剂的治疗有效剂量的一个或多个剂量，以使在大约7天的时间内不会施用超过单一剂量。
• NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS
  申请人：Blagg Brian S.J.

  公开号：US20100105630A1

  公开（公告）日：2010-04-29

  Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders.

  诺伐霉素类似物和含有这些化合物的药物组合物，可用于治疗和/或预防神经退行性疾病和自身免疫性疾病。
• Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US10548876B2

  公开（公告）日：2020-02-04

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双蒽或其衍生物、类似物或原药。
• Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US11147800B2

  公开（公告）日：2021-10-19

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双蒽或其衍生物、类似物或原药。
• COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE
  申请人：Update Pharma Inc.

  公开号：EP3024457A1

  公开（公告）日：2016-06-01